ONCT - Oncternal Therapeutics, Inc.
IEX Last Trade
0.5477
-1.162 -212.215%
Share volume: 0
Last Updated: Mon 02 Dec 2024 09:06:57 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$1.71
0.00
0.00%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-09 | 2022-11-03 | 2023-03-09 | 2023-05-04 | 2023-08-10 | 2023-11-09 | 2024-03-07 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 81.526 M | 76.170 M | 68.651 M | 58.282 M | 50.773 M | 43.195 M | 36.729 M | 29.141 M | |
| Current Assets | 80.980 M | 74.790 M | 67.290 M | 57.917 M | 50.075 M | 42.492 M | 36.059 M | 28.504 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 2.080 M | 3.936 M | 3.566 M | 3.318 M | 4.310 M | 2.001 M | 1.804 M | 899.000 K | |
| Short Term Investments | 2.080 M | 3.936 M | 3.566 M | 3.318 M | 4.310 M | 2.001 M | 1.804 M | 899.000 K | |
| Total Receivables | 0.000 | 226.000 K | 0.000 | 282.000 K | 262.000 K | 186.000 K | 0.000 | 578.000 K | |
| Current Cash | 78.900 M | 70.628 M | 63.724 M | 54.317 M | 45.503 M | 40.305 M | 34.255 M | 27.027 M | |
| Total Non-current Assets | 546.000 K | 1.380 M | 1.361 M | 365.000 K | 698.000 K | 703.000 K | 670.000 K | 637.000 K | |
| Property Plant Equipment | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Assets | 389.000 K | 1.258 M | 1.274 M | 315.000 K | 332.000 K | 412.000 K | 412.000 K | 412.000 K | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 81.526 M | 76.170 M | 68.651 M | 58.282 M | 50.773 M | 43.195 M | 36.729 M | 29.141 M | |
| Total liabilities | 7.525 M | 7.626 M | 7.682 M | 5.794 M | 5.589 M | 6.199 M | 6.677 M | 6.215 M | |
| Total current liabilities | 7.512 M | 7.626 M | 7.682 M | 5.488 M | 4.831 M | 5.152 M | 5.198 M | 6.116 M | |
| Accounts Payable | 2.519 M | 2.456 M | 2.917 M | 1.964 M | 2.224 M | 2.133 M | 1.148 M | 1.462 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 306.000 K | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 306.000 K | 0.000 | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 74.001 M | 68.544 M | 60.969 M | 52.488 M | 45.184 M | 36.996 M | 30.052 M | 22.926 M | |
| Common stock | 50.064 M | 54.212 M | 56.671 M | 58.522 M | 58.722 M | 58.964 M | 2.950 M | 59.180 M | |
| Retained earnings | -135.775 M | -146.900 M | -158.300 M | -169.787 M | -178.753 M | -188.615 M | -197.779 M | -206.167 M |